Sector News

J&J's Ethicon unit to buy NeuWave

March 10, 2016
Life sciences

Johnson & Johnson medical-device unit Ethicon agreed to buy NeuWave Medical Inc.

NeuWave developed a system that eliminates soft-tissue lesions with microwave energy and is used by cancer patients.

Ethicon said in a statement that “we continue to work to push the boundaries of access and treatment for patients for whom traditional surgery may not be an option today.”

Last May, Madison, Wis.-based NeuWave said it had raised $25 million in Series C financing. New investor Versant Ventures led the round, joined by returning backers H.I.G. BioVentures, Venture Investors and others.

Ethicon and the life-sciences division of Google Inc. formed a partnership last year to develop robots to assist surgeons. In December, Johnson & Johnson said Scott Huennekens will serve as chief executive of an independent company called Verb Surgical Inc. that emerged from the collaboration.

Ethicon expects to complete the NeuWave deal during the second quarter.

By Josh Beckerman

Source: Dow Jones Business News via Nasdaq

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”